Regents of University of Minnesota v. AGA Medical Corp.

835 F. Supp. 2d 711, 2011 WL 6256984, 2011 U.S. Dist. LEXIS 144194
CourtDistrict Court, D. Minnesota
DecidedDecember 14, 2011
DocketCase No. 07-CV-4732 (PJS/LIB)
StatusPublished
Cited by4 cases

This text of 835 F. Supp. 2d 711 (Regents of University of Minnesota v. AGA Medical Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Regents of University of Minnesota v. AGA Medical Corp., 835 F. Supp. 2d 711, 2011 WL 6256984, 2011 U.S. Dist. LEXIS 144194 (mnd 2011).

Opinion

ORDER

PATRICK J. SCHILTZ, District Judge.

Defendant AGA Medical Corporation (“AGA”) moves for summary judgment that the claims of U.S. Patent No. 6,077,-281 (the '281 patent) asserted by plaintiff Regents of the University of Minnesota (“the University”) are invalid. According to AGA, the claims are invalid for three reasons: (1) they are anticipated; (2) they are indefinite; and (3) they are not enabled. For its part, the University moves to exclude certain evidence that relates to AGA’s enablement argument.

For the reasons that follow, the Court grants summary judgment of invalidity to AGA on the basis of both anticipation and indefiniteness. But because the Court finds that AGA’s evidence with respect to enablement is untimely, the Court excludes the evidence and rejects AGA’s enablement argument.

The Court’s finding of invalidity means that the University cannot recover against AGA based on the '281 patent. And the University cannot recover against AGA based on the second patent at issue in this case — U.S. Patent No. 6,077,291 (the '291 patent) — because, in an earlier order, the Court granted summary judgment of non-infringement to AGA. Order on Mot. for SJ of Noninfringement (“Second SJ Order”) at 12-13 [Docket No. 231].1 Thus, the only issues remaining in this case relate to AGA’s declaratory-judgment coun[714]*714terclaims. Because those counterclaims all plead, in various ways, that the patents asserted by the University are invalid, not infringed, or unenforceable, the Court exercises its discretion to dismiss AGA’s remaining counterclaims as moot, and the Court directs that judgment be entered dismissing the University’s complaint.

I. BACKGROUND

The University sued AGA for allegedly infringing the '281 and '291 patents. Both patents cover medical devices for repairing heart defects. The University owns the patents, which are part of a family of four patents covering inventions made by Glad-win S. Das. The University prosecuted all four patents as Das’s assignee.

The Das patents descend from an application filed in 1992. The University abandoned the original application, but subsequent divisional applications resulted in four patents: U.S. Patent No. 5,334,217, issued in April 1994; U.S. Patent No. 5,578,045, issued in November 1996; and the '281 and '291 patents, both of which were issued on June 20, 2000. These four patents include different claims but generally share the same specification.2

Roughly speaking, all of the Das patents cover a closure device (commonly called an “occluder”) for repairing a hole between two chambers of a human heart. The occluder is delivered through a catheter that is threaded through a vein or artery until the catheter’s far end reaches the hole to be closed.

The occluder features two disks that are joined at the center. The disks, which are springy, are folded up and pushed through a catheter. The far end of the catheter is placed through the hole in the heart. The occluder is then pushed forward through the catheter until the first half of the occluder (i.e., the first disk) comes out of the catheter on the far side of the hole and springs back into its disk-like shape. The catheter is then pulled back to the near side of the hole with the second half of the occluder (i.e., the second disk) still inside the catheter. The occluder is pushed forward again until the second disk springs out, this time on the near side of the hole. The area where the two disks are joined blocks the hole, and the disks stay in position for two reasons: (1) they are bigger than the hole, and (2) they are springy. The central portion of the disk soon becomes solid in one of a number of ways, and at that point, the hole is closed.

The following drawing from the '281 patent depicts a side view of an embodiment of the occluder with both disks in their fully expanded shape:

[715]*715[[Image here]]

'281 Pat. Fig. 3.

The following series of drawings from the '281 patent show the same embodiment of the occluder as it is being deP%ed to close a hole in a patient’s heart:

[[Image here]]

'281 Pat. Figs. 8-10 (cropped and rearranged).

II. DISCUSSION

A. Standard of Review

Summary judgment is appropriate “if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed.R.Civ.P. 56(a). A dispute over a fact is “material” only if its resolution might affect the outcome of the lawsuit under the substantive law. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986). A dispute over a fact is “genuine” only if “the evidence is such that a reasonable jury could return a verdict for the nonmoving party.” Id. “The evidence of the nonmovant is to be believed, and all justifiable inferences are to be drawn in his favor.” Id. at 255, 106 S.Ct. 2505.

B. Anticipation

A patent claim is invalid as anticipated under 35 U.S.C. § 102 if a single prior-art reference discloses, expressly or inherent[716]*716ly, each limitation of the claim. See, e.g., Perricone v. Medicis Pharm. Corp., 432 F.3d 1368, 1375 (Fed.Cir.2005). Anticipation can be thought of as a kind of retrospective infringement, because “that which would literally infringe if later anticipates if earlier.” Bristol-Myers Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368, 1378 (Fed.Cir.2001). Anticipation is a question of fact, and it must be established by clear and convincing evidence. See id. at 1374; see also Teleflex, Inc. v. Ficosa N. Am. Corp., 299 F.3d 1313, 1323 (Fed.Cir.2002) (“What a prior art reference discloses in an anticipation analysis is a factual determination ....”).

According to AGA, two different devices described in two references each meet all of the limitations of claims 1, 4, and 5 of the '281 patent (the only asserted claims): (1) an occluder covered by U.S. Patent No. 3,874,388 to King; and (2) a “clamshell” occluder described in an article from 1989 by James E. Lock et al. titled Transcatheter Closure of Arterial Septal Defects: Experimental Studies, 79 Circulation 1091 (1989) (“Lock article”).3 The Court will refer to these devices, respectively, as the “King device” and the “Lock device.”4

The Court first sets out the asserted claims of the '281 patent as construed by the Court, then discusses the King and Lock devices in turn.

1. Asserted Claims of the '281 Patent

Claim 1 of the '281 patent claims:

A septal defect closure device comprising a first member and a second member

each comprising a self-expanding structure

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
835 F. Supp. 2d 711, 2011 WL 6256984, 2011 U.S. Dist. LEXIS 144194, Counsel Stack Legal Research, https://law.counselstack.com/opinion/regents-of-university-of-minnesota-v-aga-medical-corp-mnd-2011.